Researchers at IRB Barcelona have identified the mechanism by which the MAF protein promotes breast cancer metastasis, revealing a key interaction with the estrogen receptor. This finding opens up new therapeutic options for patients with high MAF levels, who may benefit from treatments aimed at preventing metastases.
Rice University bioengineers Jerzy Szablowski and Julea Vlassakis have received the National Institutes of Health Director’s New Innovator Award for their creative research projects on gene expression and cancer interactions. Szablowski is developing noninvasive methods to map gene expression, while Vlassakis is studying complex single...
Dr. Beau Webber received a two-year Translation to CURE award to study genetically engineered gamma delta T cells for treating metastatic osteosarcoma. This innovative approach aims to address the limitations of current immune-cell based therapies and offers new hope for childhood cancer treatment.
Rice University chemist Han Xiao has won a $3.2 million research grant from the National Cancer Institute to develop an epigenetic inhibitor targeting bone metastasis. The drug, based on existing bisphosphonates, aims to prevent cancer cells from spreading to other organs without affecting normal tissues.
Researchers at Nanyang Technological University discover ponatinib, an existing cancer drug, can block key steps in alternative lengthening of telomeres (ALT) mechanism. This could lead to new treatment options for ALT cancers, which currently lack targeted therapies.
Researchers have created an RNA nanoparticle therapy that disables the pathways through which multiple myeloma cells travel, stopping their spread. The therapy targets the microenvironment of the cancer and prevents the production of a protein that attracts cancer cells to blood vessels.
Researchers from Rice University and Baylor College of Medicine are developing a new 'glyco-immune' checkpoint inhibitor to train the immune system to target and kill breast cancer metastasis in bones. The therapy has shown promise in preliminary tests, including eradicating cancer in some animals.
A new Northwestern Medicine study found young adult cancer survivors (18-39 years old) are 2.6 times more likely to develop heart failure when treated with anthracyclines. The incidence is highest among leukemia and other specific cancer types.
Increased expression of Musashi 1 on breast cancer cells has significant implications for understanding dormancy and survival in bone marrow. Msi 1 knockdown led to a reduction in cancer stem cells with undetectable PD-L1, suggesting a potential therapeutic target.
Researchers at The Mount Sinai Hospital have created versatile disease models of acute myeloid leukemia (AML), allowing for accurate study of the cancer's progression and response to drugs. These models, derived from induced pluripotent stem cells, can mimic different stages of AML and are nearly identical to those found in patients.
Researchers created a three-dimensional structure that mimics bone and houses osteosarcoma cells beside immune cells, finding increased inflammation reduces chemotherapy effectiveness. The study highlights the importance of the tumor microenvironment in disease progression and treatment.
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
A study found that Spp24 inhibits osteosarcoma tumor cell proliferation, invasiveness, and promotes apoptosis. It achieves this by neutralizing bone morphogenetic protein 2.
A new drug called CADD522 blocks a gene associated with driving bone cancer's spread, increasing survival rates by 50% in mice implanted with human bone cancer. The breakthrough treatment shows promise in all main bone cancer subtypes and has the potential to save lives and reduce disability.
Scientists at St. Jude Children's Research Hospital developed a new design for chimeric antigen receptors (CARs) by adding a molecular anchor, increasing the anti-cancer activity of cellular immunotherapies in cancer models. The anchored CARs improved cancer killing and survival rates in animal models of multiple tumor types.
A new study found that the antibody-drug conjugate STRO-001 showed nanomolar cytotoxicity in 88% of cancer cell lines tested, with potent efficacy against proliferating B cells. The research supports ongoing clinical studies for patients with B-cell non-Hodgkin lymphoma.
Researchers found that EWS::FLI1 induces Slit2 expression, which activates Robo receptors and enhances Ewing sarcoma growth. Silencing Slit2 strongly inhibited Ewing sarcoma cell growth, providing an opportunity for targeted therapy.
Researchers have identified two subgroups of Ewing sarcoma that respond differently to targeted drug therapy, with the first group responding to Linsitinib and AZD1775 treatment. The study suggests that repeated biopsies may be needed over time to determine the best course of treatment for each patient.
Researchers at UVA Cancer Center have identified interleukin-1 as a crucial contributor to the development of myelofibrosis, a potentially deadly bone marrow cancer. Targeting this cytokine could prevent myelofibrosis from progressing and spare bone marrow scarring.
Researchers at the University of Missouri have successfully used click chemistry to deliver radiopharmaceuticals specifically to tumors in large dogs with bone cancer, increasing effectiveness and minimizing circulation. This breakthrough could pave the way for click chemistry-based treatments for humans with cancer in the future.
UCF researchers have designed a cerium oxide nanoparticle to protect bones against radiation damage from cancer therapy. The treatment also improves bone regeneration and kills cancer cells, reducing the risk of bone fractures and tissue damage.
A new study found that adult survivors of childhood cancer are 80% more likely to be undertreated for cardiovascular risk factors, including hypertension, diabetes, and high cholesterol. The study highlights the need for increased awareness among healthcare professionals and improved health management strategies for cancer survivors.
A new study uses artificial intelligence to predict bone fractures in cancer patients by creating a digital twin of the vertebra. The AI-assisted framework, ReconGAN, simulates how tumors affect the spine and predicts fracture risks, offering medical experts better treatment strategies and patient decisions.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
Scientists have discovered anticancer substances in kudzu roots and soy molasses that can fight cancer, especially when chemotherapy or surgery are dangerous. The isoflavonoids in these plant extracts mimic human estrogen and bind to free radicals, leading to various diseases including cancer formation.
Paczesny will explore biomarkers and a new type of immune cell to identify and regulate acute lung injury after BMT. She aims to improve understanding of signaling mechanisms in lung injury after BMT, particularly as they relate to idiopathic pneumonia syndrome.
Researchers at Rice University and Baylor College of Medicine have created an antibody with an engineered peptide that effectively targets and attacks bone tumors in breast cancer. The study shows the therapeutic efficacy is best when a moderate amount of the drug compound is delivered, offering new hope for treating bone metastases.
Sophie Paczesny's research aims to validate biomarker panels that help doctors predict chronic GVHD risk and adjust immune suppression treatments accordingly. The study uses machine learning algorithms to analyze stored plasma and blood cell samples from over 1,300 BMT recipients.
Survival rates for adult patients with relapsed acute lymphoblastic leukemia (ALL) after hematopoietic cell transplantation have increased significantly over the past two decades. The two-year overall survival rate rose from 27.8% in 2000-2004 to 54.8% in 2015-2019, despite a significant increase in patient age at relapse.
Researchers found a novel therapy called AVID200 safe and well-tolerated, with modest improvements in symptom burden, anemia, and spleen enlargement. The therapy needs to be combined with other drugs to optimize impact in patients.
Researchers discovered that acute myeloid leukemia (AML) depends on a transporter to bring in inositol, a sugar required for cells to survive. By blocking this transporter, cancer cells would starve without inositol. This method leaves normal cells unharmed as they can produce their own inositol.
Researchers at Duke University and UC Irvine identify Kenpaullone, a cancer drug, as an effective analgesic for chronic and challenging-to-treat pain. The compound enhances Kcc2 gene expression, which resets maladaptive genetic switches in neurons, leading to pain signal silencing.
Researchers at University of Virginia Health System have discovered a new treatment target for osteoporosis and bone loss from rheumatoid arthritis. A cellular protein called ELMO1 promotes the activity of osteoclasts, which break down bone, leading to excessive bone degradation.
Researchers found that remnant cholesterol levels above 24 micrograms per deciliter were associated with a 40-50% higher risk of major heart disease or stroke. The study suggests using remnant cholesterol as an additional metric for predicting cardiovascular disease and stroke risk, in addition to LDL cholesterol levels.
Researchers at Rice and Baylor are expanding their efforts to halt bone cancer metastasis using a molecule targeting osteoporosis and HER2 protein. Their goal is to improve drug concentration at tumor sites, inhibit secondary metastasis, and explore the therapeutic effect mechanism.
Researchers identified a protein called neurexin-1 in cancer stem-like cells that are resistant to chemotherapy and responsible for recurrence. Patients with higher levels of this protein have poorer outcomes and lower survival rates.
Researchers identified glypican-1 protein that prevents cancer cells from spreading to bone, reducing aggressiveness. The study provides a potential new target for future treatments and supports previous findings suggesting the protein's role in preventing tumor growth.
A recent study suggests that cancer prevalence in medieval Britain may be around 9-14%, significantly higher than the previous estimate of less than 1%. The research used x-rays and CT scans to analyze skeletal remains from six medieval cemeteries, revealing signs of malignancy in five individuals.
A landmark study by researchers from the SWOG Cancer Research Network has found that 2.8 percent of cancer patients develop osteonecrosis of the jaw within three years of starting zoledronic acid treatment. The study, which followed 3,491 patients over three years, also identified risk factors and impact on quality of life.
Researchers found that too little sugar can lead to more bone-eating cells in people with bone marrow cancer. A special type of sugar water was shown to reduce perforations and cancer growth in mice with bone marrow cancer. Further animal experiments are needed to develop a treatment for humans.
A clinical trial led by Fred Hutchinson Cancer Center found the iCanQuit app to be nearly 1.5 times more effective in helping adult smokers quit after 12 months compared to the National Cancer Institute's QuitGuide app. The study suggests that for every 100,000 smokers reached with iCanQuit, 28,000 would quit smoking.
WSU researchers have developed a new approach using soy-based compounds to reduce bone cancer cell viability and promote healthy bone cell growth. The slow release of these compounds from 3D-printed scaffolds showed promise in reducing inflammation and improving overall recovery.
Researchers at Royal Ontario Museum and McMaster University diagnosed osteosarcoma, an aggressive bone cancer, in a Centrosaurus apertus dinosaur fossil. The diagnosis was made possible by advanced imaging techniques and microscopic analysis of the fossil bone.
Researchers at MU successfully treated bone cancer in dogs with a vaccine that stimulates the immune system against abnormal proteins specific to the patient's tumor. The treatment outperformed chemotherapy, resulting in over 400 days of cancer survival for dogs compared to about 270 days for those receiving traditional chemotherapy.
Researchers identify key genes driving bone cancer spread to lungs and develop a gene therapy approach that stops the spread in mice. The breakthrough could lead to 'kinder' treatments for children with bone cancer, saving lives.
A new IOF review emphasizes the importance of long-term follow-up to maintain bone health in childhood cancer survivors. The study highlights the need for careful monitoring and management to prevent premature onset of low bone mineral density and improve fracture risk.
A study published in JNCI Cancer Spectrum found that diets high in soy foods are associated with a decreased risk of osteoporotic bone fractures in pre-menopausal breast cancer survivors. Soy intake was linked to a 77% reduced risk of fractures, particularly among younger women.
A case study documents a highly malignant bone tumor in a 240-million-year-old stem-turtle from the Triassic period. The appearance of the tumor conforms with present-day periosteal osteosarcoma in humans, providing valuable insights into the history of cancer in tetrapod evolution.
Scientists discovered complex genetic rearrangements in Ewing Sarcomas that can take years to form, potentially leading to earlier diagnosis and treatment. These findings suggest that some childhood cancers may be detectable before they reveal themselves as disease.
Scientists at MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer in mice, enabling better understanding and treatment of bone metastasis. The model reveals how cancer cells interact with bone and bone resident cells over time, providing insights into the disease's progression.
Acute myeloid leukemia (AML) has a poor five-year survival rate of less than 20%. Researchers at the National University of Singapore identified a novel molecular pathway involving circadian clock gene SHARP1, which causes AML growth. Removing or reducing SHARP1 levels can stop leukemic cell growth.
A new study from St. Jude Children's Research Hospital and the American University of Beirut Medical Center demonstrates effective childhood cancer treatment in a refugee setting. The institution adapted its services to prioritize curable cases, showcasing a viable model for crisis response.
A recent study found a genetic relationship between hCMV reactivation and GVHD, suggesting personalized antiviral treatments could reduce complications in stem cell transplant patients. Researchers sequenced the DNA of 77 donors and recipients, identifying similarities between hCMV peptides and those expressed in GVHD-affected tissue.
Researchers are developing customized 3D implants that can be printed in real-time during tumor surgery, allowing for more precise treatment of bone cancer. This innovative technology has the potential to improve patient outcomes and expand surgical options.
A genetic study has identified a subset of osteosarcoma patients who may respond to IGF1R inhibitors based on their genetic profile. The study found that 10% of patients with a specific mutation in growth factor signalling genes could benefit from existing drugs.
Archaeologists discover a 14-16 year old with bone cancer from the pre-Colombian settlement Cerro Brujo, Panama, dated around 1300 AD. The individual was buried in a fetal position with clay pots and a shell trumpet, indicating a ritual burial.
Researchers have identified two sarcoma subtypes, leiomyosarcoma and pleomorphic, as likely susceptible to immunotherapy. The study analyzed 81 patient samples, revealing patterns of immune response that suggest these subtypes can be targeted with checkpoint inhibitors.
A recent study found that cord blood transplants may be the best option for high-risk leukemia patients, offering a lower risk of relapse compared to traditional transplants. Researchers at Fred Hutchinson Cancer Center discovered that these patients have better outcomes against leukemia and related bone marrow disorders.
A team of researchers discovered the oldest evidence for cancer and bony tumors in human fossils, dating back 1.7 million years. The findings push back the origins of these diseases from recent times to deep prehistory.
Researchers at University of Illinois successfully tested nanoparticle drug delivery in dogs with naturally occurring bone cancers, which are similar to human bone tumors. The study demonstrated anti-cancer activity and tolerance to high doses without toxicity in the dogs.